Want to see KR:000520 full AI Analyst Report?

Samil Pharmaceutical Co., Ltd. (000520) Price & Analysis

― Followers

000520 Stock Chart & Stats

₩7690.00

-₩90.00(-1.16%)

Oct 29, 2026

―

Day’s Range― - ―

52-Week Range₩5,500.00 - ₩12,860.00

Previous CloseN/A

VolumeN/A

Average Volume (3M)70.16K

Market Cap

₩165.72B

Enterprise Value₩310.98B

Total Cash (Recent Filing)₩6.11B

Total Debt (Recent Filing)₩176.05B

Price to Earnings (P/E)―

Beta0.04

Next Earnings

Nov 18, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.96%

Share Statistics

EPS (TTM)-1763.67

Shares Outstanding21,691,810

10 Day Avg. Volume63,861

30 Day Avg. Volume70,155

Financial Highlights & Ratios

PEG Ratio-0.01

Price to Book (P/B)1.54

Price to Sales (P/S)0.98

P/FCF Ratio-15.23

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Historical Revenue GrowthRevenue growth in the 2022–2024 period indicates that the company has previously demonstrated an ability to expand its business. That historical commercial traction provides a foundation for recovery if operating execution, product demand, and profitability improve.

Positive Gross MarginA gross margin of approximately 32% means the company continues to retain meaningful value after direct production costs. This gross-profit base can support operating recovery and investment in the business if revenue stabilization and cost control restore operating profitability.

Established Pharmaceutical PlatformParticipation across medicine development, manufacturing, and sales gives Samil Pharmaceutical an established operating platform in its domestic market. Existing pharmaceutical capabilities and distribution access can support continued product commercialization and provide a base for longer-term recovery.

Bears Say

Severe Profitability DeteriorationThe swing from operating profit to deep operating losses, alongside an approximately negative 18% TTM net margin, shows that the current business model is not converting revenue into earnings. Persistent losses could weaken reinvestment capacity and erode financial resilience.

Persistent Cash BurnConsistently negative free cash flow indicates that the company is not currently self-funding after investment spending. Weak operating cash conversion increases reliance on financing and balance-sheet capacity, limiting flexibility to invest, absorb setbacks, or withstand continued losses.

Rising Leverage And Equity ErosionHigher debt relative to equity makes the balance sheet more exposed while losses continue to reduce the capital base. If weak earnings persist, rising leverage can constrain future capital allocation, increase dependence on external funding, and reduce financial flexibility.

000520 FAQ

What was Samil Pharmaceutical Co., Ltd.’s price range in the past 12 months?

Samil Pharmaceutical Co., Ltd. lowest stock price was ₩5500.00 and its highest was ₩12860.00 in the past 12 months.

What is Samil Pharmaceutical Co., Ltd.’s market cap?

Samil Pharmaceutical Co., Ltd.’s market cap is ₩165.72B.

When is Samil Pharmaceutical Co., Ltd.’s upcoming earnings report date?

Samil Pharmaceutical Co., Ltd.’s upcoming earnings report date is Nov 18, 2026 which is in 19 days.

How were Samil Pharmaceutical Co., Ltd.’s earnings last quarter?

Samil Pharmaceutical Co., Ltd. released its earnings results on Aug 14, 2026. The company reported -₩359.853 earnings per share for the quarter.

Is Samil Pharmaceutical Co., Ltd. overvalued?

According to Wall Street analysts Samil Pharmaceutical Co., Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Samil Pharmaceutical Co., Ltd. pay dividends?

Samil Pharmaceutical Co., Ltd. pays a Annually dividend of ₩72.727 which represents an annual dividend yield of 0.96%. See more information on Samil Pharmaceutical Co., Ltd. dividends here

What is Samil Pharmaceutical Co., Ltd.’s EPS estimate?

Samil Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Samil Pharmaceutical Co., Ltd. have?

Samil Pharmaceutical Co., Ltd. has 21,691,810 shares outstanding.

What happened to Samil Pharmaceutical Co., Ltd.’s price movement after its last earnings report?

Samil Pharmaceutical Co., Ltd. reported an EPS of -₩359.853 in its last earnings report. Following the earnings report the stock price went down -0.442%.

Which hedge fund is a major shareholder of Samil Pharmaceutical Co., Ltd.?

Currently, no hedge funds are holding shares in KR:000520

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Samil Pharmaceutical Co., Ltd.

Samil Pharmaceutical Co., Ltd. is a South Korean pharmaceutical company founded in 1947 that develops, manufactures, and sells a range of healthcare products. While its portfolio includes various medicines and medical devices, it has a particular specialization in ophthalmology (eye care). The company engages in the development of new drugs and also provides Contract Development and Manufacturing Organisation (CDMO) services.